Effects of medical therapies for acromegaly on glucose metabolism

European Journal of Endocrinology

Volumn 169, Issue 1, 2013, Pages 99-108

  Urbani, C ^a   Sardella, C ^a   Calevro, A ^b   Rossi, G ^a   Scattina, I ^a   Lombardi, M ^a   Lupi, I ^a   Manetti, L ^a   Martino, E ^a   Boggazzi, F ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOSE; INSULIN; OCTREOTIDE; PEGVISOMANT;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ACTIVITY; DISEASE CONTROL; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MONOTHERAPY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACROMEGALY; ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, SOMATOTROPIN; RETROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 84879948356     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0032     Document Type: Article

References (38)

1. LeRoith D & Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nature Clinical Practice. Endocrinology & Metabolism 2007 3 302-310. (doi:10.1038/ncpendmet0427)
2. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152. (doi:10.1210/er.2002-0022)
3. Ben-Shlomo A & Melmed S. Acromegaly. Endocrinology and Metabolism Clinics of North America 2008 37 101-122, viii. (doi:10.1016/j.ecl.2007.10.002)
4. Sonksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A & Nabarro JD. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. Journal of Clinical Endocrinology and Metabolism 1967 27 1418-1430. (doi:10.1210/jcem-27-10-1418)
5. Wass JA, Cudworth AG, Bottazzo GF,Woodrow JC & Besser GM. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clinical Endocrinology 1980 12 53-59. (doi:10.1111/j.1365-2265.1980. tb03132.x)
6. Moller N & Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009 30 152-177. (doi:10.1210/er.2008-0027)
7. Hansen I, Tsalikian E, Beaufrere B, Gerich J, HaymondM & Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. American Journal of Physiology 1986 250 E269-E273.
8. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M & Ghigo E. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. Journal of Endocrinological Investigation 2006 29 1017-1020.
9. Alberti KG, Christensen NJ, Christensen SE, Hansen AP, Iversen J, Lundbaek K, Seyer-Hansen K & Orskov H. Inhibition of insulin secretion by somatostatin. Lancet 1973 2 1299-1301. (doi:10.1016/S0140-6736(73)92873-0)
10. Koop BL, Harris AG & Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. European Journal of Endocrinology 1994 130 581-586. (doi:10.1530/eje.0.1300581)
11. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM & Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. Journal of Clinical Endocrinology and Metabolism 2002 87 1797-1804. (doi:10.1210/jc.87.4.1797)
12. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology 2003 59 492-499. (doi:10.1046/j.1365-2265.2003.01876.x)
13. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P & Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. Journal of Endocrinological Investigation 2002 25 502-507.
14. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P & Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. Journal of Clinical Endocrinology and Metabolism 2009 94 1500-1508. (doi:10.1210/jc.2008-2332)
15. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759. (doi:10.1016/S0140-6736(01)06844-1)
16. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2005 90 5684-5691. (doi:10.1210/ jc.2005-0331)
17. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C & Orskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism 2005 90 5627-5631. (doi:10.1210/jc.2005-0531)
18. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP & Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. European Journal of Endocrinology 2003 149 521-527. (doi:10.1530/eje.0.1490521)
19. Rose DR & Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormone & IGF Research 2002 12 418-424. (doi:10.1016/S1096-6374(02) 00083-7)
20. Lindberg-Larsen R, Moller N, Schmitz O, Nielsen S, Andersen M, Orskov H & Jorgensen JO. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 1724-1728. (doi:10.1210/jc.2006-2276)
21. Higham CE, Rowles S, Russell-Jones D, Umpleby AM & Trainer PJ. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 2459-2463. (doi:10.1210/jc.2008-2086)
22. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K &Melmed S. A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 3141-3148. (doi:10.1210/jc.2009-2670)
23. Bogazzi F, Cosci C, Sardella C, Costa A, Manetti L, Gasperi M, Rossi G, Bartalena L & Martino E. Identification of acromegalic patients at risk of developing colonic adenomas. Journal of Clinical Endocrinology and Metabolism 2006 91 1351-1356. (doi:10.1210/jc.2005-2500)
24. American Diabetes Association. Diagnosis and Classification of diabetes mellitus. Diabetes Care 2011 34 (Suppl 1) S62-S69. (doi:10.2337/dc11-S062)
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
26. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495. (doi:10.2337/ diacare.27.6.1487)
27. Matsuda M. Measuring and estimating insulin resistance in clinical and research settings. Nutrition, Metabolism, and Cardiovascular Diseases 2010 20 79-86. (doi:10.1016/j.numecd. 2009.07.007)
28. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G & Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and Metabolism 2000 85 2402-2410. (doi:10.1210/jc.85.7.2402)
29. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462-1470. (doi:10.2337/diacare.22.9.1462)
30. Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994 17 152-154. (doi:10.2337/diacare.17.2.152)
31. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK & Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 2008 16 1901-1907. (doi:10.1038/oby.2008.307)
32. Phillips DI, Clark PM, Hales CN & Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Medicine 1994 11 286-292. (doi:10.1111/j.1464-5491. 1994. tb00273.x)
33. Bogazzi F, Manetti L, Lombardi M, Giovannetti C, Raffaelli V, Urbani C, Scattina I, Pepe P, Iannelli A, Martino E et al. Impact of different cut-off limits of peak GH after GHRH-arginine stimulatory test, single IGF1 measurement, or their combination in identifying adult patients with GH deficiency. European Journal of Endocrinology 2011 164 685-693. (doi:10.1530/EJE-10-1068)
34. Petersenn S, Buchfelder M, Reincke M, Strasburger CM, Franz H, Lohmann R, Quabbe HJ & Plockinger U. Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. European Journal of Endocrinology 2008 159 525-532. (doi:10.1530/EJE-08-0498)
35. De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A & Giustina A. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 2007 10 227-232. (doi:10.1007/s11102-007-0037-7)
36. Madsen M, Poulsen PL, Orskov H, Moller N & Jorgensen JO. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. Journal of Clinical Endocrinology and Metabolism 2011 96 2405-2413. (doi:10.1210/ jc.2011-0654)
37. Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ & HaffnerSM. Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010 33 2098-2103. (doi:10.2337/ dc10-0165)
38. Chen NY, Chen WY, Bellush L, Yang CW, Striker LJ, Striker GE & Kopchick JJ. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995 136 660-667. (doi:10.1210/en.136. 2.660)